Suzanne Cohen

As Executive Director and Head of Bioscience, Asthma and Skin Immunity at AstraZeneca, I lead drug discovery research teams focusing on pathways central to asthma, allergic and inflammatory diseases. I also serve as a member of our Respiratory and Immunology early-stage project governance and leadership team.

I provide strategic direction to the research teams I lead, determining the chosen mechanisms to study. My core focus is research that helps build scientific understanding within the field of immunology, and the discovery new of therapies for diseases of high unmet need, including asthma and potentially atopic dermatitis. In asthma specifically, we are working to target the underlying causes of disease to develop future curative treatments.

With over 20 years of industry experience, I am an inventor on multiple patents, including IGE molecules (US 7,959,917 B2), interleukin (IL)-4 receptor alpha (US 8,092,804 B2),  GM-CSF receptor (US 9,085,628 B2) and Il-33 forms and antibodies (US10668150B2). I am renowned in the IL-33 field through my novel discovery of IL-33 oxidation and its biological implications.

I completed by undergraduate degree in Natural Sciences from the University of Cambridge and have a D.Phil. in Immunology from the University of Oxford.